Studies have been performed in this laboratory on plasma 17-hydroxycorticosteroid levels in patients with endocrine and non-endocrine diseases (12). During the course of these investigations, it became apparent that there are disease states, particularly primary adrenal insufficiency and hypopituitarism, in which plasma 17-hydroxycorticosteroid levels determined before and after ACTH administration may give a more accurate picture of adrenal capacity than single plasma 17-hydroxycorticosteroid levels. These findings prompted an evaluation of plasma 17-hydroxycorticosteroid response to ACTH in patients with a variety of disorders of the adrenal cortex as compared with normal subjects.
(Submitted for publication January 26, 1955; accepted February 23, 1955) The response of the adrenal cortex to exogenous ACTH has been recognized as one of the more specific and quantitative tests of adrenal function (1) . Changes in the 24-hour excretion values of urinary 17-ketosteroids and 17-hydroxycorticosteroids during ACTH administration have proved to be valuable indices of adrenocortical capacity (2, 3) . With (6) (7) (8) (9) (10) (11) .
Studies have been performed in this laboratory on plasma 17-hydroxycorticosteroid levels in patients with endocrine and non-endocrine diseases (12) . During the course of these investigations, it became apparent that there are disease states, particularly primary adrenal insufficiency and hypopituitarism, in which plasma 17-hydroxycorticosteroid levels determined before and after ACTH administration may give a more accurate picture of adrenal capacity than single plasma 17-hydroxycorticosteroid levels. These findings prompted an evaluation of plasma 17-hydroxycorticosteroid response to ACTH in patients with a variety of disorders of the adrenal cortex as compared with normal subjects. 2Trainee, National Institute of Arthritis and Metabolic Diseases. ' Damon Runyon Research Fellow. previously described (12) . Normal values in this laboratory range from 4 to 32 micrograms per 100 ml. plasma (12) . 2 . The intravenous route of ACTH administration was selected as the most direct method of adrenal stimulation, since it avoids the variability of absorption and local tissue inactivation which have been reported to occur when ACTH is injected intramuscularly (2) .
Because of the contradictory reports in the literature concerning optimal dosage and duration of administration of ACTH, it appeared impractical to aim for maximal adrenocortical stimulation or for the attainment of a steady state of steroid output (2, 11, 13) . It seemed more informative to adhere to a standardized method of adrenocortical stimulation, and to compare the response of patients with disordered adrenal function with that of normal individuals under these standard conditions. The technic of the ACTH test used was as follows:
Twenty-five mgm. (25 i.u.) of ACTH (Armour ACTHAR-C, Lot R-K23601) 4 freshly dissolved in 500 ml. of 5 per cent dextrose and water was administered at a constant rate over a period of four hours. Twentyfive ml. blood specimens to which heparin' was added were drawn at the beginning and end of the ACTH infusion. Specimens were centrifuged, and 10 ml. plasma immediately separated and refrigerated. 17, 21-dihydroxy-20-ketosteroid determinations were performed within 72 hours. (In a few instances indicated in the Tables where  the intravenous route could not 
RESULTS
The results are summarized graphically in Figure 1 .
A. Normal subjects Four-hour intravenous ACTH tests were performed in eleven normal individuals ranging in administration (see Figure 1 and Table II ). In four-cases (patients J. B., F. K.,'C. H., and R. F.),
the control values of plasma 17-hydroxycorticosteroids were within the normal range (12) . However, the response of all four patients to ACTH administration was distinctly abnormal in that post-ACTH levels of plasma 17-hydroxycorticosteroids failed to show an increase over control values. The following is a brief summary of the findings in one of these four patients.
A 13-year old white boy (R. F.) had had numerous bouts of nausea and vomiting following minor. respiratory infections. since the age of 6. He had sustained two severe episodes of hypotension, one of which was followed by a prolonged period of nitrogen retention. When first seen in Babies Hospital, he was diffusely tanned, with one deeply pigmented scar. Blood pressure was 90/60, urinary corticoids 7 were 0.4 to 1.9 mgm. per 24 hours, and serum sodium was 128 mEq. per liter. Fourhour intravenous ACTH tests were performed on two successive days. The control plasma 17-hydroxycorticosteroi4. level was 16. microgramhs per cent (see Table   II ). After the second ACTH infusion, the level was 13 micrograms per cent. On a regimen of added salt, DOC trimethylacetate, and cortisone, the patient has gained weight and felt well. Repeated serum sodium determinations have been normal.
The eighth patient, M. K., a woman with Addison's disease who was in the third trimester of pregnancy when studies were performed, had a control plasma 17-hydroxycorticosteroid value of 23 micrograms per cent. After two hours of intravenous ACTH infusion, her plasma level was 26 micrograms per cent (not considered a significant rise), and at the fourth hour, the level was 4 micrograms per cent.8
C. Hypopituitarism
The effect of ACTH administration was studied in ten patients with hypopituitarism (see Table  III ). Control plasma 17-hydroxycorticosteroid levels were low, ranging from 0 to 12 micrograms per cent. After ACTH the levels attained by most of these patients were considerably lower than those found in ACTH-stimulated normal individuals (compare Tables I and III) perplasia. One patient (S. B.) was studied before surgery, and two (K. R., and C. P.) after
In three patients (W. R., H. P., and M. B.) the first but prior to a second adrenalectomy. plasma 17-hydroxycorticosteroid responses to It will be seen in Table IV [12] .) The plasma levels attained at the end of the ACTH test appeared to be more char- acteristic than any set increment over the control plasma levels. This relative constancy of response suggests a certain uniformity in the secretory capacity of the normal human adrenal cortex, under the conditions of this testing method. Similar findings have been reported by Eik-Nes, Sandberg, Nelson, Tyler, and Samuels (11) . Diminished responses to intravenous ACTH were encountered in three groups of subjects: patients with 1) Addison's disease, 2) hypopituitarism, and 3) congenital adrenal virilism due to bilateral adrenal hyperplasia. In the patients with Addison's disease, ACTH consistently failed to cause a rise in plasma 17-hydroxycorticosteroid values. This was the rule whether the period of ACTH administration was brief or prolonged, and whether the control plasma 17-hydroxycorticosteroid level was low or within normal limits. The uniform failure of plasma -17-hydroxycorticosteroid levels to rise following ACTH is at variance with the findings of Eik-Nes and his coworkers (11) who noted appreciable though subnormal plasma 17-hydroxycorticosteroid rises within two hours after the start of ACTH infusions in two of six patients with Addison's disease. In this laboratory, the only patients who as a group have failed to show adrenocortical response to exogenous ACTH have been those with primary adrenal instfficiency.
In contrast to the Addisonian patients, those with hypopituitarism invariably showed an increase in plasma 17-hydroxycorticosteroid values following ACTH. However, in seven of the ten cases studied the magnitude of the increase was much smaller than that found in normal subjects.
In patients with hypopituitarism, it is relatively simple to evaluate thyroid function by means of the basal metabolic rate, the thyroidal uptake of radioactive iodine, the plasma level of proteinbound iodine, and the response of the thyroid to stimulation by thyrotropin. Gonadotropic hypofunction can be documented both by clinical criteria and by the absence of urinary gonadotropins.
The assessment of adrenocortical function and of the patient's need for adrenal replacement therapy are not as easily accomplished. The low urinary steroid excretion values and the urinary steroid response to ACTH which have been used as indices of adrenal activity in patients with hypopituitarism, may be influenced by disordered thyroid and gonadal function as well as by the poorlyunderstood effects of a chronic debilitating disease. At the present time it is not possible to predict with certainty whether an individual patient with hypopituitarism will require cortisone for optimal maintenance. It may be possible when these patients have been followed for a longer period of time to correlate their need for adrenal replacement therapy with the diminished responsiveness to ACTH. Eventually then, the ACTH test may serve as a guide in planning such therapy.
The diminished response of plasma 17-hydroxycorticosteroid levels to ACTH stimulation found in most patients with congenital adrenal-hyperplasia is in accord with the results of previous investigations (9, 10, 14, 15) . It should be reemphasized that none of the patients in this group had the so-called "salt-losing syndrome," and none had clinical evidence of adrenal insufficiency. The reduced adrenocortical response to ACTH appears to support the hypothesis that patients with this type of adrenal virilism have an inborn error of steroid metabolism characterized by a partial enzymatic block in the synthesis of 17-hydroxycorticosterone from its precursors (15) (16) (17) (18) .
Two groups of patients showed an exaggerated plasma 17-hydroxycorticosteroid rise after ACTH: 1) patients with Cushing's syndrome due to bilateral adrenal hyperplasia; and 2) normal women in the third trimester of pregnancy. In the patients with Cushing's syndrome, this excessive response occurred even after the removal of one of the hyperplastic adrenal glands. During the course of normal pregnancy urinary (21) and plasma (22) corticosteroid levels are known to rise progressively until term. However, the source of these "adrenal-like" steroids has not been clearly established. It is also known that urinary steroid values in patients with Addison's disease show progressive increases with advancing pregnancy (23, 24) . Again, the source of these "corticoids" remains a matter of debate. In the one pregnant Addisonian patient studied in this clinic, the rise in urinary steroid excretion values was again observed, and paralleled a rise in plasma 17-hydroxycorticosteroid levels. It seemed important to determine whether the source of these substances could be stimulated by ACTH. Accordingly, a standard ACTH test was performed in the third trimester of the pregnancy. No further increase in plasma 17-hydroxycorticosteroids was demonstrated. This confirms the results of Hills, Venning, Dohan, Webster, and Richardson (24) who noted no increase in urinary "corticoids" after ACTH in two pregnant patients with Addison's disease. These findings prompted studies in normal women in the third trimester of pregnancy. The patients showed increases in plasma 17-hydroxycorticosteroids after ACTH which were far in excess of the normal.
From these data, it seems permissible to draw two conclusions: 1) The increase of Porter-Silber reactive substances, measured as plasma 17-hydroxycorticosteroids which occurred in advancing pregnancy in this patient with Addison's disease, was due to an extra-adrenal source which could not be further stimulated by ACTE; 2 2) The increasing concentration of these substances in normal pregnancy may be due both to an extraadrenal source and to 'the adrenal cortex, but the excessive corticosteroid increase following ACTH must be due to an enhanced responsiveness of the adrenal cortex itself.
SUMMARY
The usefulness of the plasma 17,21-dihydroxy-20-ketosteroid response to intravenously-administere1 ACTH in the assessment of adrenocortical function has been confirmed. After a standard ACTH test, changes in plasma 17-hydroxycorticosteroid levels were rather constatit in normal individuals. Under these conditions, no increase in plasma levels was encountered in patients with Addison's disease. Subnormal rises in: plasma 17-hydroxycorticosteroid values were demonstrated in patients with hypopituitarism and congenital adrenal hyperplasia. Adrenocortical responses to ACTH in excess of the normal occurred in women in the third trimester of normal pregnancy and in patients with Cushing's syndrome due to bilateral adrenal hyperplasia. In the 'latter patients, bilateral subtotal adrenalectomy was followed by subnormal plasma 17- hydroxycorticosteroid response to ACTH. Addenda (a) Since these studies were completed Eik-Nes and his co-workers have reported data on the effects of intravenous ACTH administration on plasma 17-OH-corticosteroid. levels in various non-endocrine disorders, in Addison's disease, and in one patient with Gushing's syndrome (25) .
(b) Two additional patients with Cushing's syndrome due to bilateral adrenocortical hyperplasia have been tested with ACTH in the manner described, and showed a similar hyper-responsiveness.
